Clinical Efficacy of Pimobendan (UD-CG 115 BS) in Patients with Chronic Congestive Heart Failure

Le résumé fourni par la source

The pyridazoline derivative UD-CG 115 BS (pimobendan) is a noneatecholamine. nonglyeoside new inotropic compound with potent vasodilator properties that exerts stiμlatory myocardial effects by increasing the Ca2†affinity of cardiac contractile proteins, thus improving Ca2† utilization. The aim of the present study was to characterize and quantify the hemodynamic effects of oral UD-CG 115 BS in 25 patients with idiopathic congestive cardiomyopathy (NYHA stage III) and compare these to the action of the β1-receptor agonist dobutamine. UD-CG 115 BS 5 mg p.o. increased cardiac output, cardiac index, and stroke volume index by approximately 60“;. With only minor changes in heart rate, ventricular tilling pressures decreased (-40%;.) and there was a decline in pulmonary and systemic vascular resistance (-50%;). as well as in systolic, diastolic. and mean pulmonary artery pressure (-35%;). The effects of 5 mg UD-CG I 15 BS were comparable to the optimal dose of dobutamine. while 10 mg induced significantly more pronounced hemodynamic changes. The effects of UD-CG 115 BS lasted for at least 12 h. No major side effects were observed. A continuous treatment with 10 mg of UD-CG 115 BS/day over a period of 5 days resulted in a significantly improved response to β-adrenoceptor stiμlation while endogeneous plasma catecholamines fell down to nearly normal values. It is concluded that UD-CG 115 BS. with its unique receptor independent mechanism of action, may represent a new therapeutic approach for management of congestive heart failure patients

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.